antiphospholipid syndrome

Summary

Summary: The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).

Top Publications

  1. ncbi Challenges in the diagnosis of the antiphospholipid syndrome
    Katrien Devreese
    Coagulation Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium
    Clin Chem 56:930-40. 2010
  2. ncbi International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
    S Miyakis
    St George Hospital, University of New South Wales, Sydney, Australia
    J Thromb Haemost 4:295-306. 2006
  3. ncbi Pathogenesis of antiphospholipid syndrome: understanding the antibodies
    Pier Luigi Meroni
    Department of Internal Medicine, University of Milan, Via della Pace 9, 20122 Milan, Italy pierluigi meroni unimi it
    Nat Rev Rheumatol 7:330-9. 2011
  4. ncbi Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
    Ricard Cervera
    Institut Clínic d Infeccions i Immunologia ICII, Hospital Clinic, and Institut d Investigacions Biomè diques August Pi i Sunyer IDIBAPS, Barcelona, Catalonia, Spain
    Arthritis Rheum 46:1019-27. 2002
  5. ncbi Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies
    Cloé Comarmond
    Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Pitie Salpetriere, Department of Internal Medicine, Universite Pierre et Marie Curie, Paris 6, Paris, France
    Autoimmun Rev 12:752-7. 2013
  6. ncbi Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome
    Gisele Zandman-Goddard
    Lecturer of Internal Medicine, Sackler Faculty of Medicine, Tel Aviv University, Israel Head of the Department of Medicine C, Wolfson Medical Center, Holon, Israel
    Semin Arthritis Rheum 36:297-315. 2007
  7. pmc Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
    Guillermina Girardi
    Department of Medicine, Hospital for Special Surgery Weill Medical College, Cornell University, 535 East 70th Street, New York, New York 10021, USA
    J Clin Invest 112:1644-54. 2003
  8. ncbi The geoepidemiology of the antiphospholipid antibody syndrome
    Martina Biggioggero
    Division of Rheumatology, Department of Internal Medicine University of Milan, Istituto G Pini, Italy
    Autoimmun Rev 9:A299-304. 2010
  9. ncbi Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome
    R Teruel
    Centro Regional de Hemodonacion, University of Murcia, Murcia, Spain
    J Thromb Haemost 9:1985-92. 2011
  10. pmc Antiphospholipid antibody tests: spreading the net
    M L Bertolaccini
    Lupus Research Unit, The Rayne Institute, St Thomas Hospital, London SE1 7EH, UK
    Ann Rheum Dis 64:1639-43. 2005

Detail Information

Publications366 found, 100 shown here

  1. ncbi Challenges in the diagnosis of the antiphospholipid syndrome
    Katrien Devreese
    Coagulation Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium
    Clin Chem 56:930-40. 2010
    The antiphospholipid syndrome (APS) is an important cause of acquired thromboembolic complications and pregnancy morbidity. Its diagnosis is based on clinical and laboratory criteria, defined by strict guidelines...
  2. ncbi International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
    S Miyakis
    St George Hospital, University of New South Wales, Sydney, Australia
    J Thromb Haemost 4:295-306. 2006
    ..experimental insights, since the 1999 publication of the Sapporo preliminary classification criteria for antiphospholipid syndrome (APS), had been addressed at a workshop in Sydney, Australia, before the Eleventh International Congress ..
  3. ncbi Pathogenesis of antiphospholipid syndrome: understanding the antibodies
    Pier Luigi Meroni
    Department of Internal Medicine, University of Milan, Via della Pace 9, 20122 Milan, Italy pierluigi meroni unimi it
    Nat Rev Rheumatol 7:330-9. 2011
    Antiphospholipid antibodies (aPL) are both diagnostic markers for, and pathogenic drivers of, antiphospholipid syndrome (APS)...
  4. ncbi Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
    Ricard Cervera
    Institut Clínic d Infeccions i Immunologia ICII, Hospital Clinic, and Institut d Investigacions Biomè diques August Pi i Sunyer IDIBAPS, Barcelona, Catalonia, Spain
    Arthritis Rheum 46:1019-27. 2002
    To analyze the clinical and immunologic manifestations of antiphospholipid syndrome (APS) in a large cohort of patients and to define patterns of disease expression.
  5. ncbi Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies
    Cloé Comarmond
    Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Pitie Salpetriere, Department of Internal Medicine, Universite Pierre et Marie Curie, Paris 6, Paris, France
    Autoimmun Rev 12:752-7. 2013
    b>Antiphospholipid syndrome (APS) is characterized by recurrent thrombosis and pregnancy morbidity in association with the persistent presence of circulating antiphospholipid antibodies (aPL)...
  6. ncbi Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome
    Gisele Zandman-Goddard
    Lecturer of Internal Medicine, Sackler Faculty of Medicine, Tel Aviv University, Israel Head of the Department of Medicine C, Wolfson Medical Center, Holon, Israel
    Semin Arthritis Rheum 36:297-315. 2007
    ....
  7. pmc Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
    Guillermina Girardi
    Department of Medicine, Hospital for Special Surgery Weill Medical College, Cornell University, 535 East 70th Street, New York, New York 10021, USA
    J Clin Invest 112:1644-54. 2003
    b>Antiphospholipid syndrome (APS) is defined by recurrent pregnancy loss and thrombosis in the presence of antiphospholipid (aPL) Ab's...
  8. ncbi The geoepidemiology of the antiphospholipid antibody syndrome
    Martina Biggioggero
    Division of Rheumatology, Department of Internal Medicine University of Milan, Istituto G Pini, Italy
    Autoimmun Rev 9:A299-304. 2010
    ..Such an association is the formal classification tool for the antiphospholipid syndrome (APS)...
  9. ncbi Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome
    R Teruel
    Centro Regional de Hemodonacion, University of Murcia, Murcia, Spain
    J Thromb Haemost 9:1985-92. 2011
    ..Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are autoimmune diseases characterized by a high TF expression in monocytes.
  10. pmc Antiphospholipid antibody tests: spreading the net
    M L Bertolaccini
    Lupus Research Unit, The Rayne Institute, St Thomas Hospital, London SE1 7EH, UK
    Ann Rheum Dis 64:1639-43. 2005
    ..the hypothesis that testing for new antiphospholipid antibody specificities may help to identify the antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) with thrombosis who are repeatedly negative ..
  11. ncbi Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future
    Ali A Mehdi
    American University of Beirut, Beirut, Lebanon
    Eur J Clin Invest 40:451-64. 2010
    b>Antiphospholipid syndrome (APS) is a systemic autoimmune vascular disease characterized by recurrent thrombotic episodes and/or obstetric complications...
  12. ncbi Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome
    Elena Ortona
    Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanita, Rome, Italy
    Blood 116:2960-7. 2010
    b>Antiphospholipid syndrome (APS) is an autoimmune disease characterized by arterial and venous thrombosis, recurrent abortions, and antiphospholipid antibodies (aPL)...
  13. ncbi OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement
    Luis R Lopez
    Corgenix Inc, 12061 Tejon Street, Westminster, CO 80234, USA
    Ann N Y Acad Sci 1051:313-22. 2005
    ..SLE), systemic sclerosis (SSc), and rheumatoid arthritis (RA); and (2) those with primary and secondary antiphospholipid syndrome (APS)...
  14. ncbi Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome
    Michael Mahler
    INOVA Diagnostics, Inc, San Diego, CA 32131 1638, USA
    Autoimmun Rev 12:313-7. 2012
    b>Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by frequent clotting in arteries and veins and/or miscarriages...
  15. ncbi Hyperactivity in a mouse model of the antiphospholipid syndrome
    A Katzav
    Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv, Israel
    Lupus 10:496-9. 2001
    In the antiphospholipid syndrome (APS), antibodies to a complex of phospholipids and beta2-glycoprotein I (beta2-GPI) are associated with recurrent thromboembolic events, spontaneous abortions, thrombocytopenia and central nervous system ..
  16. pmc Impaired fibrinolysis in the antiphospholipid syndrome
    Katie A Krone
    Cleveland Clinic Lerner College of Medicine, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Rheumatol Rep 12:53-7. 2010
    The antiphospholipid syndrome (APS) is characterized by venous and/or arterial thrombosis, or recurrent fetal loss, in the presence of antiphospholipid antibodies (APL)...
  17. ncbi Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome
    David Tanne
    Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel
    Neurobiol Dis 30:56-64. 2008
    Experimental antiphospholipid syndrome (eAPS) induced by immunization with beta(2)-glycoprotein I (beta(2)-GPI) causes behavioral hyperactivity...
  18. ncbi Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients
    R Cervera
    Servei de Malalties Autoimmunes, Hospital Clinic, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    Ann Rheum Dis 68:1428-32. 2009
    To identify the main causes of morbidity and mortality in patients with antiphospholipid syndrome (APS) during a 5-year period and to determine clinical and immunological parameters with prognostic significance.
  19. ncbi Annexinopathies
    M J Hayes
    Div of Cell Biology, University College London Institute of Ophthalmology, 11 43 Bath Street, London ECI V 9EL, UK
    Subcell Biochem 45:1-28. 2007
    ..of acute promyelocytic leukaemia, and the under-expression of annexin 5 on placental trophoblasts in the antiphospholipid syndrome. In this chapter we will outline some of the more recent observations in regard to these conditions, and ..
  20. ncbi A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways
    Konstantinos Ritis
    First Division of Internal Medicine, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece
    J Immunol 177:4794-802. 2006
    ..studies using the complement inhibitor compstatin revealed that complement activation is triggered by antiphospholipid syndrome (APS) IgG and leads to the induction of a TF-dependent coagulant activity...
  21. ncbi Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry"
    Ricard Cervera
    Department of Autoimmune Diseases, Institut Clinic de Medicina i Dermatologia, Hospital Clinic, Barcelona, Catalonia, Spain
    J Autoimmun 32:240-5. 2009
    To describe the clinical and laboratory features, as well as the precipitating factors, treatment and outcome of patients with catastrophic antiphospholipid syndrome (APS).
  22. ncbi Neurological manifestations of antiphospholipid syndrome
    Carlos E M Rodrigues
    University of Sao Paulo, Sao Paulo, Brazil
    Eur J Clin Invest 40:350-9. 2010
    Neurologic disorders are among the most common and important clinical manifestations associated with the antiphospholipid syndrome (APS). It is characterized by diverse neurological manifestations...
  23. ncbi Atypical movement disorders in antiphospholipid syndrome
    Davide Martino
    Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, London, United Kingdom
    Mov Disord 21:944-9. 2006
    Movement disorders have only rarely been reported in association with antiphospholipid syndrome (APS). In such cases, chorea is the most common disorder observed, with occasional reports of hemidystonia, Parkinsonism, and hemiballism...
  24. pmc European registry of babies born to mothers with antiphospholipid syndrome
    Arsene Mekinian
    Service de Medecine Interne, Universite Paris 13, AP HP, Hopital Jean Verdier, 93140 Bondy, France
    Ann Rheum Dis 72:217-22. 2013
    ..study aimed to describe the long-term outcome and immunological status of children born to mothers with antiphospholipid syndrome, to determine the factors responsible for childhood abnormalities, and to correlate the child's ..
  25. ncbi The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe
    R Cervera
    Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain
    Lupus 18:889-93. 2009
    ..A total cohort of 1000 patients with antiphospholipid syndrome (APS), derived from 13 countries (Belgium, Bulgaria, Denmark, France, Germany, Greece, Hungary, Israel, ..
  26. ncbi Oxidized LDL induces in vitro lymphocyte activation in antiphospholipid syndrome
    Renata Laczik
    Intensive Care Unit, 3rd Department of Medicine, Institute of Internal Medicine, University of Debrecen Medical and Health Science Center, Móricz Zs Street 22, 4004 Debrecen, Hungary
    Autoimmunity 43:334-9. 2010
    ..In antiphospholipid syndrome (APS), oxLDL molecules form complexes with beta2GPI and become target antigens for autoantibodies, which ..
  27. ncbi Infant perinatal thrombosis and antiphospholipid antibodies: a review
    M C Boffa
    Service d Hematologie, Hopital Jean Verdier, Assistance Publique, Hospitaux de Paris, Bondy, France
    Lupus 16:634-41. 2007
    ..Thrombosis treatments were diverse. This analysis suggests that women with aPL should be investigated for other thrombophilic risk factors and that aPL should be detected systematically at birth in the offspring of mothers with APS...
  28. ncbi Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?
    Laura Andreoli
    Rheumatology and Clinical Immunology Unit, Spedali Civili, Piazzale Spedali Civili 1, University of Brescia, 25123 Brescia, Italy
    J Autoimmun 30:51-7. 2008
    ..Patients with primary antiphospholipid syndrome (PAPS) may develop full-blown SLE but there is no evidence for markers predictive for that.
  29. ncbi The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation
    Yoshie Sakai
    Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Arthritis Rheum 60:2457-67. 2009
    ..against phosphatidylserine/prothrombin complex (anti-PS/PT), the latter being highly associated with the antiphospholipid syndrome (APS)...
  30. pmc Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway
    Melissa J Mulla
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06510, USA
    Am J Reprod Immunol 62:96-111. 2009
    ..The objective of this study was to determine the effects of aPL on trophoblast function and the mechanisms involved...
  31. ncbi 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study
    Savino Sciascia
    Dipartimento di Malattie Rare, Immunologiche, Ematologiche ed Immunoematologiche, Ospedale Torino Nord Emergenza San G Bosco ed Università di Torino, Turin, Italy
    Inflamm Res 61:809-16. 2012
    To test the inflammation and oxidative stress hypothesis in antiphospholipid syndrome (APS) patients and to identify possible associations with clinical and laboratory features of the disease.
  32. ncbi Seronegative antiphospholipid syndrome
    Rabih Nayfe
    Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11 0236, Riad El Solh, Beirut 1107 2020, Lebanon
    Rheumatology (Oxford) 52:1358-67. 2013
    ....
  33. ncbi Paroxysmal non-kinesigenic dyskinesia in antiphospholipid syndrome
    Marc Engelen
    Department of Neurology, Academic Medical Centre, Amsterdam, The Netherlands
    Mov Disord 20:111-3. 2005
    ..classifiable as a paroxysmal nonkinesigenic dyskinesia, occurring as the first manifestation of primary antiphospholipid syndrome (PAPS)...
  34. ncbi Pathogenesis of the antiphospholipid syndrome
    Rohan Willis
    Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555 0883, USA
    Semin Thromb Hemost 38:305-21. 2012
    The presence of pathogenic antiphospholipid antibodies (aPL) is the characterizing feature of the antiphospholipid syndrome (APS), mediating the recurrent pregnancy loss and thrombosis typical of the disease, through their action on ..
  35. ncbi Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies
    S Shrot
    Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Lupus 11:736-43. 2002
    ..The mechanism involved in these CNS manifestations remains to be elucidated...
  36. ncbi Platelets and the antiphospholipid syndrome
    R T Urbanus
    Department of Clinical Chemistry and Haematology, University Medical Center, Utrecht, The Netherlands
    Lupus 17:888-94. 2008
    The antiphospholipid syndrome is a non-inflammatory autoimmune disease characterised by the presence of antiphospholipid antibodies in the plasma of patients with venous or arterial thrombosis or recurrent complications of pregnancy...
  37. ncbi Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy
    A Ruffatti
    Department of Clinical and Experimental Medicine, University of Padua, Italy
    Thromb Res 123:482-7. 2009
    A relationship between antibody profile and pregnancy outcome in patients with a previous diagnosis of primary antiphospholipid syndrome (APS) has not been clearly documented.
  38. ncbi Hyperactivity induced by antiphospholipid syndrome serum
    Assaf Menachem
    Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Ann N Y Acad Sci 1173:422-6. 2009
    b>Antiphospholipid syndrome (APS) is a multisystem disorder characterized by arterial and venous thrombosis, pregnancy morbidity, and neuropsychiatric manifestations. Antiphospholipid IgG injected intracerebroventricularly (i.c.v...
  39. ncbi High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus
    Guillermo Ruiz-Irastorza
    Servicio de Medicina Interna, Hospital de Cruces, Universidad del Pais Vasco Euskal Herriko Unibertsitatea, Bizkaia, Spain
    Arch Intern Med 164:77-82. 2004
    ..Whether antiphospholipid syndrome (APS) is the cause of increased irreversible organ damage and mortality in lupus patients is not well ..
  40. ncbi Atherosclerosis and antiphospholipid syndrome
    Luis J Jara
    Clinical Research Unit and Rheumatology Department, Hospital de Especialidades Centro Medico La Raza, Mexico City, Mexico
    Clin Rev Allergy Immunol 25:79-88. 2003
    ..Patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) have a high risk for atherosclerotic cardiovascular events...
  41. ncbi Systemic antiphospholipid syndrome and atherosclerosis
    Luis J Jara
    Research Division, Hospital de Especialidades Centro Medico La Raza, IMSS, Seris y Zaachila s n, Colonia La Raza, Mexico City 02990, Mexico
    Clin Rev Allergy Immunol 32:172-7. 2007
    ..b>Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombophilic state and circulating ..
  42. ncbi Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines
    R A Asherson
    Rheumatic Diseases Unit, University of Cape Town School of Medicine, Cape Town, South Africa
    Lupus 12:530-4. 2003
    The term 'catastrophic' antiphospholipid syndrome (APS) is used to define an accelerated form of APS resulting in multiorgan failure...
  43. ncbi The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study
    B de Laat
    Department of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands
    J Thromb Haemost 7:1767-73. 2009
    Diagnosis of the antiphospholipid syndrome (APS) is difficult as a result of limited specificity of existing assays for detecting clinically relevant antiphospholipid antibodies...
  44. ncbi The abdominal manifestations of the antiphospholipid syndrome
    I Uthman
    Division of Rheumatology, Faculty of Medicine, American University of Beirut, Medical Center, PO Box 113 6044, Beirut, Lebanon
    Rheumatology (Oxford) 46:1641-7. 2007
    To study the abdominal manifestations of the antiphospholipid syndrome (APS).
  45. ncbi Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view
    P L Meroni
    Division of Rheumatology, Istituto G Pini, Department of Internal Medicine, University of Milan, IRCCS Istituto Auxologico Italiano, Milan Italy
    Lupus 19:453-6. 2010
    ..Understanding the different pathogenic mechanisms of aPL-associated miscarriages may help in improving our therapeutic approach particularly in recurrent cases not responsive to the usual treatment...
  46. pmc Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome
    Vijaya Murthy
    University of Texas Medical Branch, Galveston
    Arthritis Rheum 65:3186-93. 2013
    ..and a subgroup that bind specifically to domain IV/V of β2 GPI, with clinical manifestations of the antiphospholipid syndrome (APS) in 3 patient groups and to evaluate the pathogenicity of IgA anti-β2 GPI in a mouse model of ..
  47. ncbi [Traditional risk factors for cardiovascular disease in primary antiphospholipid syndrome (APS) when compared with secondary APS: a study with 96 patients]
    A R Ribeiro
    Serviço de Reumatologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, SP
    Acta Reumatol Port 35:36-41. 2010
    To evaluate the prevalence of traditional risk factors in patients with primary antiphospholipid syndrome (APS) in comparison to those with systemic lupus erythematosus-secondary APS.
  48. ncbi Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin
    Tamara Y Carroll
    Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA
    Am J Reprod Immunol 66:286-96. 2011
    ..These findings may help to explain why women with antiphospholipid syndrome, who are treated with heparin to prevent early pregnancy loss, remain at increased risk of developing ..
  49. ncbi Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells
    Nadine Prinz
    Institute of Clinical Chemistry and Laboratory Medicine, University Medical Centre Mainz, Mainz, Germany
    Blood 118:2322-32. 2011
    The antiphospholipid syndrome (APS) is an autoimmune disease characterized by thromboembolic events and/or fetal loss in the presence of antiphospholipid antibodies (aPLs)...
  50. ncbi Does seronegative antiphospholipid syndrome really exist?
    Ricard Cervera
    Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain
    Autoimmun Rev 11:581-4. 2012
    The diagnosis of seronegative (SN-) antiphospholipid syndrome (APS) has been suggested for patients with clinical manifestations indicative of APS but with persistently negative results in the commonly used assays to detect anti-..
  51. ncbi Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure
    N J Sebire
    Department of Histopathology, Imperial College School of Medicine, St Mary s Hospital, Paddington, London, W2 1PG, UK
    Hum Reprod 17:1067-71. 2002
    ..This study examines products of conception (POC) from early pregnancy failures to investigate the mechanism of pregnancy loss...
  52. ncbi Val247Leu β2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: systematic review and meta-analysis
    Antonio Javier Chamorro
    Department of Autoimmune Diseases, Institut Clinic de Medicina i Dermatologia, Hospital Clinic, Villarroel 170, 08036, Barcelona, Catalonia, Spain
    Autoimmun Rev 11:705-12. 2012
    ..of the Val247Leu polymorphism of the β(2)-glycoproteinI (β(2)-GPI) gene may be associated with antiphospholipid syndrome (APS), and, among patients with APS, with the production of anti-β(2)-GPI antibodies or the development ..
  53. ncbi Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment
    Carlos Pérez-Sánchez
    Instituto Maimonides de Investigación Biomédica de Córdoba IMIBIC Reina Sofia Hospital, Cordoba, Spain
    Blood 119:5859-70. 2012
    ..the role of oxidative stress in the pathogenesis and the prothrombotic or proinflammatory status of antiphospholipid syndrome (APS) remain unknown...
  54. pmc Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays
    Akito Tsutsumi
    Division of Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1 1 1 Tennodai, Tsukuba, 305 8575, Japan
    Mod Rheumatol 16:158-64. 2006
    Antibodies against prothrombin are detected by enzyme immunoassays (EIA) in sera of patients with antiphospholipid syndrome (APS)...
  55. pmc Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies
    Michael D Lockshin
    Hospital for Special Surgery and Weill Cornell Medical College, New York, New York
    Arthritis Rheum 64:2311-8. 2012
    ....
  56. pmc Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus
    Anna Broder
    Division of Rheumatology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA
    J Rheumatol 40:30-3. 2013
    Antiphospholipid antibodies (aPL) play an active role in the pathogenesis of the antiphospholipid syndrome (APS)...
  57. ncbi Coexistence of the antiphospholipid syndrome and abdominal aortic aneurysm
    Martine Szyper-Kravitz
    Center for Autoimmune Diseases and Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel
    Isr Med Assoc J 10:48-51. 2008
    The antiphospholipid syndrome is characterized by recurrent fetal loss, venous and/or arterial thrombosis, and thrombocytopenia associated with elevated titers of lupus anticoagulant and anticardiolipin antibodies...
  58. ncbi Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab
    Horacio Berman
    Department of Autoimmune Diseases, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, Barcelona, Catalonia, Spain
    Autoimmun Rev 12:1085-90. 2013
    The catastrophic variant of the antiphospholipid syndrome (APS) is characterized by thrombosis in multiple organs developing over a short period of time...
  59. ncbi Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Thrombosis Center, University Hospital, Padova, Italy
    J Thromb Haemost 8:237-42. 2010
    The characteristics and the clinical course of antiphospholipid syndrome (APS) in high-risk patients that are positive for all three recommended tests that detect the presence of antiphospholipid (aPL) antibodies have not been described.
  60. ncbi Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome
    Laura Andreoli
    Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy
    J Autoimmun 38:J197-208. 2012
    ..in the improvement of the management of pregnancy in women with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS)...
  61. ncbi Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome
    G Hayem
    Hĵpital Bichat, Paris, France
    Lupus 10:346-51. 2001
    ..potential links between antiOxLDL antibodies and the clinical and biological features of secondary antiphospholipid syndrome (II APLS) associated with systemic lupus erythematosus (SLE)...
  62. ncbi Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome
    Aviva Katzav
    Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
    Behav Brain Res 169:289-93. 2006
    The antiphospholipid syndrome (APS) includes systemic and central nervous system (CNS) pathology associated with antibodies to a complex of phospholipids and beta(2)-glycoprotein I (beta(2)-GPI)...
  63. ncbi The prevalence of coeliac disease antibodies in patients with the antiphospholipid syndrome
    R Shamir
    Division of Paediatric Gastroenterology and Nutrition, Meyer Children s Hospital of Haifa, Haifa, Israel
    Lupus 12:394-9. 2003
    ..coeliac disease (CD) has been reported in various autoimmune disorders, buthas not been studied in the antiphospholipid syndrome (APS)...
  64. ncbi Features associated with epilepsy in the antiphospholipid syndrome
    Yehuda Shoenfeld
    Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel
    J Rheumatol 31:1344-8. 2004
    To assess the frequency of epilepsy in primary and secondary antiphospholipid syndrome (APS); to analyze the clinical and laboratory features characterizing those with epilepsy in a cohort of 538 patients with APS; and to find associated ..
  65. ncbi Hughes syndrome crosses boundaries
    Guillermo Ruiz-Irastorza
    Lupus Research Unit, The Rayne Institute, St Thomas Hospital, London SE1 7EH, UK
    Autoimmun Rev 1:43-8. 2002
    ..Recently, classification criteria for definite antiphospholipid syndrome have been proposed and validated...
  66. ncbi Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS')
    Jose Luis Rodriguez-Garcia
    Lupus Research Unit, The Rayne Institute, King s College London School of Medicine, St Thomas Hospital, UK
    Ann Rheum Dis 71:242-4. 2012
    ..currently provides a growing number of isolated case reports of patients with clinically well-defined antiphospholipid syndrome (APS) and persistently negative antiphospholipid antibodies (aPL), there are no studies including a ..
  67. pmc Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome
    C Hamid
    Research Institute of Healthcare Sciences, University of Wolverhampton, UK
    Ann Rheum Dis 66:1000-7. 2007
    To determine the effects of primary antiphospholipid syndrome (PAPS)-derived anti-beta(2)GPI antibodies on gene expression in human umbilical vein endothelial cells (HUVEC) by gene profiling using microarrays.
  68. ncbi New autoantigens in the antiphospholipid syndrome
    Cristiano Alessandri
    Lupus Clinic, Reumatologia, Dipartimento di Medicina Interna e Specialita Mediche, Sapienza Universita di Roma, Rome, Italy
    Autoimmun Rev 10:609-16. 2011
    The antiphospholipid syndrome (APS) is an autoimmune disease characterized by arterial and venous thrombosis, recurrent miscarriages or fetal loss, and circulating antiphospholipid antibodies (aPL)...
  69. ncbi Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies
    Giovanni Triolo
    Cattedra di Reumatologia, Istituto di Clinica Medica, Policlinico and University of Palermo, Palermo, Italy
    Arthritis Rheum 48:728-31. 2003
    ....
  70. ncbi Antiphospholipid antibodies affect human endometrial angiogenesis
    Nicoletta Di Simone
    Department of Obstetrics and Gynecology, Catholic University of Sacred Heart, Rome, Italy
    Biol Reprod 83:212-9. 2010
    ..aPL) represent an important risk factor for thrombosis and recurrent miscarriage in patients with antiphospholipid syndrome (APS). The mechanisms of aPL-mediated pregnancy failure have been researched...
  71. ncbi A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome
    D Erkan
    Department of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, New York 10021, SA
    Rheumatology (Oxford) 41:924-9. 2002
    Antiphospholipid antibodies (aPL) are major risk factors for thrombosis. Other clinical factors exist in antiphospholipid syndrome (APS) patients which may have an additive or preventive effect on thrombosis...
  72. ncbi Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010
    W Branch
    Department of Obstetrics and Gynecology, Salt Lake City, UT 84132, USA
    Lupus 20:158-64. 2011
    ..Force of the 13th International Congress identified and discussed five general topics within 'Obstetric' Antiphospholipid Syndrome (APS) that contained areas of controversy or uncertainty: recurrent early miscarriage (REM), fetal death,..
  73. ncbi Secondary prevention in thrombotic antiphospholipid syndrome
    V Pengo
    Clinical Cardiology, Thrombosis Centre, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy
    Lupus 21:734-5. 2012
    Secondary prevention of venous thromboembolism in antiphospholipid syndrome (APS) is usually made using vitamin K antagonists (VKAs) to maintain an international normalized ratio (INR) between 2.0 and 3.0...
  74. ncbi The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome
    Der Yuan Chen
    Department of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ROC
    Clin Chim Acta 411:1084-9. 2010
    Human parvovirus B19 (B19) infection has been identified as a trigger of antiphospholipid syndrome (APS). However, the precise role of B19-VP1 unique region (VP1u) in patients with antiphospholipid syndrome remains unclear.
  75. ncbi Catastrophic antiphospholipid syndrome (CAPS)
    Savino Sciascia
    Lupus Research Unit, The Rayne Institute, Division of Women s Health, King s College London, UK
    Best Pract Res Clin Rheumatol 26:535-41. 2012
    Catastrophic antiphospholipid syndrome (CAPS) is a very severe variant of the classic APS, characterised by clinical evidence of multiple organ involvement developing over a very short period of time, histopathological evidence of ..
  76. ncbi The pathogenesis of neural injury in animal models of the antiphospholipid syndrome
    Aviva Katzav
    Department of Neurology and Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer 52621, Israel
    Clin Rev Allergy Immunol 38:196-200. 2010
    Circulating antiphospholipid antibodies (aPL) are associated with central nervous system dysfunction in antiphospholipid syndrome (APS) patients and in a mouse model of APS...
  77. ncbi Cardiac manifestations in the antiphospholipid syndrome
    Felicia Tenedios
    Hospital for Special Surgery, Department of Rheumatology, Weill Medical College of Cornell University, 535 East 70 th Street, New York, NY 10021, USA
    Rheum Dis Clin North Am 32:491-507. 2006
    ..aPL may be associated with accelerated atherosclerosis in APS patients. Valve disease is the most important and most common cardiac manifestation of APS. The precise mechanism by which valves become deformed is not yet fully known...
  78. ncbi Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background
    Aviva Katzav
    Department of Neurology and Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, 52621, Israel
    Neurobiol Aging 32:272-9. 2011
    The antiphospholipid syndrome (APS) is characterized by antiphospholipid antibodies (aPL) and vascular brain disease which is often associated with dementia...
  79. ncbi Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor
    Fabio Fischetti
    Department of Physiology and Pathology, University of Trieste, Trieste, Italy
    Blood 106:2340-6. 2005
    ..of rats receiving antiphospholipid (aPL) immunoglobulin G (IgG) purified from the sera of patients with antiphospholipid syndrome. aPL IgG had no procoagulant effect, but it caused rapid endothelial deposition of fibrinogen, followed ..
  80. ncbi Types of pregnancy loss in recurrent miscarriage: implications for research and clinical practice
    L Bricker
    Department of Obstetrics and Gynaecology, University of Liverpool, Liverpool Women s Hospital, Crown St, Liverpool L8 7SS, UK
    Hum Reprod 17:1345-50. 2002
    ..The aim of this study was to assess whether recurrent pregnancy loss (RPL) patterns differ according to causal/associated conditions, suggesting differing disease processes...
  81. ncbi Pregnancy and catastrophic antiphospholipid syndrome
    José A Gómez-Puerta
    Rheumatology Department, Hospital Clinic, Barcelona, Spain
    Clin Rev Allergy Immunol 36:85-90. 2009
    b>Antiphospholipid syndrome (APS) is clearly related to maternal morbidity...
  82. ncbi Hematopoietic stem cell transplantation for systemic lupus erythematosus, the antiphospholipid syndrome and bullous skin diseases
    Alberto M Marmont
    Divisione di Ematologia e Trapianto di Cellule Staminali, Azienda Ospedaliera Universitaria S Martino, Genoa, Italy
    Autoimmunity 41:639-47. 2008
    ..Similar encouraging results have been obtained in the primary antiphospholipid syndrome (APS) and in bullous disorders of the skin.
  83. ncbi High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome
    P R J Ames
    Rheumatology and Haematology, Airedale District General Hospital, Steeton, UK
    Lupus 19:711-6. 2010
    ..atherogenic tendency of systemic lupus erythematosus but the picture is unclear in thrombotic primary antiphospholipid syndrome (PAPS)...
  84. ncbi Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis
    Chary Lopez-Pedrera
    Hospital Universitario Reina Sofia, Cordoba, Spain
    Arthritis Rheum 58:2835-44. 2008
    ..In this study, using proteomic techniques, we evaluated changes in protein expression of monocytes from patients with antiphospholipid syndrome (APS) related to the pathophysiology of the syndrome.
  85. ncbi Pathophysiology of thrombosis and potential targeted therapies in antiphospholipid syndrome
    Olga Amengual
    Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Curr Vasc Pharmacol 9:606-18. 2011
    The antiphospholipid syndrome (APS) is an autoimmune disease in which recurrent vascular thrombosis, pregnancy morbidity or a combination of these events is associated with the persistent presence of circulating antiphospholipid ..
  86. pmc Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome
    Patricia Redecha
    Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA
    J Clin Invest 118:3453-61. 2008
    Women with antiphospholipid syndrome (APS), a condition characterized by the presence of antiphospholipid antibodies (aPL), often suffer pregnancy-related complications, including miscarriage...
  87. ncbi Prolactin's role in the pathogenesis of the antiphospholipid syndrome
    S Praprotnik
    Department of Rheumatology, University Clinical Center Ljubljana, Ljubljana, Slovenia
    Lupus 19:1515-9. 2010
    ..Currently, there is a lack of data regarding hyperprolactinaemia in patients with the antiphospholipid syndrome. Hence, this study was carried out in order to evaluate the prevalence and clinical significance of ..
  88. ncbi Acute pulmonary edema, capillaritis and alveolar hemorrhage: pulmonary manifestations coexistent in antiphospholipid syndrome and systemic lupus erythematosus?
    V A Nguyen
    Department of Dermatology, Innsbruck Medical University, Innsbruck, Austria
    Lupus 14:557-60. 2005
    ..Pulmonary manifestations of antiphospholipid syndrome (APS) are similar and include, apart from pulmonary embolism and pulmonary hypertension, pulmonary ..
  89. ncbi Effects of low-molecular-weight heparin on adhesion and vesiculation of phospholipid membranes: a possible mechanism for the treatment of hypercoagulability in antiphospholipid syndrome
    Mojca Frank
    Department of Rheumatology, University Medical Center, Ljubljana, Slovenia
    Ann N Y Acad Sci 1173:874-86. 2009
    Heparins represent an efficient treatment of acute thrombosis and obstetric complications in antiphospholipid syndrome (APS)...
  90. ncbi Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome
    Spiros Dendrinos
    2nd Department of Obstetrics and Gynecology, Aretaieion Hospital, Medical School, University of Athens, Athens, Greece
    Int J Gynaecol Obstet 104:223-5. 2009
    ..To compare low-molecular-weight (LMW) heparin plus low-dose aspirin with intravenous immunoglobulin (IVIG) in the treatment of antiphospholipid antibody syndrome in women with recurrent spontaneous abortions before 10 weeks of gestation...
  91. ncbi Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002
    R L Brey
    Department of Medicine, Division of Neurology, University of Texas Health Science Center San Antonio, Texas 78229 3900, USA
    Lupus 12:508-13. 2003
    ..stroke is the only neurological manifestation accepted as a clinical diagnostic criterion for the antiphospholipid syndrome (APS)...
  92. ncbi Heparin treatment in pregnancy loss: Potential therapeutic benefits beyond anticoagulation
    Guillermina Girardi
    Department of Medicine, Hospital for Special Surgery Weill Medical College of Cornell University, New York, NY 10021, USA
    J Reprod Immunol 66:45-51. 2005
    Interventions with heparin therapies have increased fetal survival in patients with antiphospholipid syndrome (APS). In this review, several physiological and pharmacological effects of heparin are described...
  93. ncbi Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression
    N Agmon-Levin
    The Zabludowicz Center for Autoimmune Diseases and Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel
    Ann Rheum Dis 70:145-50. 2011
    b>Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thrombosis, obstetric complications and the presence of anti-phospholipid antibodies such as anti-β2GPI-Abs...
  94. ncbi Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer
    Y Shoenfeld
    Department of Medicine B and Research Center for Autoimmune Diseases, Sheba MedicalCenter, Tel Hashomer, Israel
    Lupus 12:436-42. 2003
    ..of aPL by intracerebro-ventricular (ICV) administration of immunoglobulins (IgG) from patients with antiphospholipid syndrome (APS)...
  95. ncbi Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome
    Aviva Katzav
    Dept of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv, Israel
    Immunobiology 207:47-50. 2003
    ..Antiphospholipid antibodies (aPL) are a heterogeneous group of antibodies detected in patients with antiphospholipid syndrome (APS), which is associated with thrombosis, pregnancy losses, and thrombocytopenia.
  96. ncbi Anti-thyroid antibodies and antiphospholipid syndrome: evidence of reduced fecundity and of poor pregnancy outcome in recurrent spontaneous aborters
    Caterina De Carolis
    UO Center for the Prevention, Diagnosis and Therapy of Recurrent Spontaneous Abortion, ASL RMC, Rome, Italy
    Am J Reprod Immunol 52:263-6. 2004
    To determine the presence of anti-thyroid antibodies in patients with primary antiphospholipid syndrome (APS) [antiphospholipid antibodies (aPL) + recurrent spontaneous abortion (RSA)], compare APS alone with APS and thyroid autoimmunity ..
  97. ncbi Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report
    M Lockshin
    Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY 10021, USA
    Lupus 12:518-23. 2003
    ..Pulmonary hypertension: the Committee recommends intensive anticoagulation with warfarin and clinical trials of bosentan, epoprostenol and other new agents...
  98. ncbi Antiphospholipid syndrome infectious origin
    M Blank
    Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Clin Immunol 24:12-23. 2004
    b>Antiphospholipid syndrome (APS) is characterized by the presence of pathogenic autoantibodies against beta 2-glycoprotein-I (beta 2GPI)...
  99. ncbi Antiphospholipid syndrome
    Guillermo Ruiz-Irastorza
    Service of Internal Medicine, Hospital de Cruces University of the Basque Country, Bizkaia, Spain
    Lancet 376:1498-509. 2010
    The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency...
  100. ncbi Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome
    Julia Francis
    Institute of Reproductive and Developmental Biology, Wolfson and Weston Research Centre for Family Health, Imperial College London, Hammersmith Campus, London, UK
    Mol Hum Reprod 12:435-42. 2006
    b>Antiphospholipid syndrome (APS), characterized by circulating antiphospholipid (aPL) antibodies, is a major cause of early pregnancy failure and placental insufficiency...
  101. pmc Annexin A2: biology and relevance to the antiphospholipid syndrome
    E Cockrell
    Division of Pediatric, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
    Lupus 17:943-51. 2008
    ..In this article, we review the role of these interactions in the activation of endothelial cells by aPL . The influence of these antibodies on the ability of annexin A2 to enhance t-PA-mediated plasminogen activation is also discussed...

Research Grants62

  1. ANTICARDIOLIPIN ANTIBODIES AND OXIDIZED PHOSPHOLIPIDS
    Joseph Witztum; Fiscal Year: 2004
    ..g. aggressive anti-inflammatory and/or antioxidant interventions). ..
  2. Antiphospholipid antibodies and lupus: new molecular targets for treatment
    Emilio B Gonzalez; Fiscal Year: 2013
    ..associated with thrombosis and pregnancy loss in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Thrombosis is an important cause of morbidity and mortality in APS and SLE patients with aPL Abs...
  3. Predictors of Pregnancy Outcome in SLE and APS
    Jane E Salmon; Fiscal Year: 2012
    Pregnancy complications in women with the antiphospholipid syndrome (APS) and/or SLE include recurrent miscarriage, preeclampsia, placental insufficiency, and intrauterine growth restriction (IUGR)...
  4. Pathogenesis of autoimmune endocarditis: roles for Fc receptors and integrins?
    Bryce Binstadt; Fiscal Year: 2012
    ..of the cardiac valves occurs in rheumatic fever (rheumatic carditis) and in SLE and the related antiphospholipid syndrome (Libman-Sacks endocarditis)...
  5. Regulation of the anti-phospholipid response in SLE
    Anne Davidson; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Antiphospholipid syndrome (APS) is a devastating autoimmune condition that causes recurrent blood clots and has no effective ..
  6. Anti-Phospholipid Multiplex For Pathologic Epitopes
    Paul O Neilsen; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): This project will help delineate the true nature of antigens in antiphospholipid syndrome (APS)...
  7. The Role of Complement in the Pathogenesis of Preeclampsia
    MICHAEL PAUL TRIEBWASSER; Fiscal Year: 2013
    ..from mouse models of the targeted knock outs of complement components and regulators, a mouse model of antiphospholipid syndrome, and observational studies of human placentas supports involvement of complement activation in ..
  8. Regulation of the anti-phospholipid response in SLE
    Anne Davidson; Fiscal Year: 2009
    ..Our long term goal is to define the interactions of the crucial pathways that contribute to induction and propagation of the anti-phospholipid syndrome so as to best devise individualized therapies for patients with SLE. ..
  9. Discovery of Novel Interventions of the Antiphospholipid Syndrome
    Chieko Mineo; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The antiphospholipid syndrome (APS) is an autoimmune disease characterized by a markedly increased risk of thromboses and cardiovascular diseases resulting from elevated levels of circulating ..
  10. CD46 AND RISK VARIANTS: EXPANDING ROLES IN DISEASE AND DISSECTING MEMBRANE DYNAMI
    JOHN PATTERSON ATKINSON; Fiscal Year: 2013
    ..targeted resequencing of multiple genes implicated in several large cohorts of patients with PE, lupus, antiphospholipid syndrome, and aHUS. Complement and clotting genes will initially receive the most attention...
  11. NOVEL BIOMARKERS FOR MECHANISTIC DIAGNOSIS OF THE ANTIPHOSPHOLIPID SYNDROME
    JACOB RAND; Fiscal Year: 2010
    ..of diagnostic and therapeutic responses for blood and vascular dysfunction - specifically, the antiphospholipid syndrome (APS) an autoimmune thrombotic condition that is reported to be responsible for ~10% of patients with ..
  12. Post-9/11 Incidence of Systemic Autoimmune Diseases in the FDNY Cohort
    Mayris P Webber; Fiscal Year: 2013
    ..The following SAID diagnoses will be included: systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis (SSc;both diffuse and limited), inflammatory myositis (dermatomyositis, ..
  13. Stroke and aPL: Community-Based Clinicopathological Study
    STEVEN RICHARD LEVINE; Fiscal Year: 2012
    ..abstract_text> ..
  14. Genetic and Cellular Determinants of Arterial Thrombosis
    Roy L Silverstein; Fiscal Year: 2010
    ..Core F will provide a curriculum and career development support for physicians training in clinical thrombosis research in SCCOR laboratories. ..
  15. PROTEIN Z DEPENDENT PROTEINASE INHIBITOR
    George J Broze; Fiscal Year: 2011
    ..define the relationship between PZ and ZPI deficiency and thrombotic disease with an emphasis on the antiphospholipid syndrome, atherosclerosis, and potential mechanisms for the development of acquired PZ/ZPI deficiency...
  16. Complement Activation and Hypertensive Diseases of Pregnancy
    Anne M Lynch; Fiscal Year: 2012
    ..If our hypothesis is proven there may be therapeutic implications as several complement inhibitors are now available that target various components of the complement system thus modifying the effects of the inflammatory cascade. ..
  17. Platelet Microvesicles
    Perumal Thiagarajan; Fiscal Year: 2013
    ..clearance of microvesicles in vivo and to test the hypothesis that microvesicles causes thrombosis in antiphospholipid syndrome. PUBLIC HEALTH RELEVANCE: Narrative When platelets are activated, they release small membrane fragments ..
  18. Investigation of Beta2-glycoprotein I Complexes in Antiphospholipid Syndrome
    Natalia Beglova; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Antiphospholipid syndrome (APS) is an autoimmune disease characterized clinically by thrombosis and/or recurrent fetal loss...
  19. Oklahoma Rheumatic Disease Research Cores Center
    Judith A James; Fiscal Year: 2013
    ..abstract_text> ..
  20. Protein disulfide isomerases: A new class of antithrombotic targets
    Bruce Furie; Fiscal Year: 2013
    ..Kenneth Bauer. The Center will work to develop a new class of antithrombotic agents directed against PDl with both antiplatelet and anticoagulant properties. ..
  21. PLATELET SUFACE ACTIVATION IN HEMOSTASIS AND THROMBOSIS
    SANFORD SHATTIL; Fiscal Year: 1993
    ..Overall, these studies should lead to a more detailed understanding of the platelet membrane events required for normal hemostasis and the role of membrane activation in hemorrhagic and thrombotic disorders...
  22. THERAPY WITH ANNEXINS FOR ANTIPHOSPHOLIPID SYNDROME
    MARIA BEGONA CAMPOS NACIFF; Fiscal Year: 2004
    ..The results obtained with this work will provide useful treatment strategies to ameliorate the symptoms associated with the antiphospholipid syndrome.
  23. Mechanisms of aPL antibody-induced pregnancy loss
    Jane Salmon; Fiscal Year: 2005
    The antiphospholipid syndrome (APS), characterized by thrombosis and pregnancy loss that occurs in the presence of antiphospholipid (aPL) antibodies, is a leading cause of miscarriage and maternal and fetal morbidity...
  24. ANTIPHOSPHOLIPID ANTIBODIES IN THROMBOSIS
    Reginald Chukwuocha; Fiscal Year: 2000
    ..abnormalities including recurrent thrombosis, fetal loss, thrombocytopenia and cerebral involvement ("Antiphospholipid syndrome", APS) in systemic lupus erythematous (SLE) are associated with the production of anticardiolipin ..
  25. PATHOPHYSIOLOGY OF ANTIPHOSPHOLIPID ANTIBODY SYNDROMES
    Thomas Ortel; Fiscal Year: 2003
    ..These studies will improve our understanding of the role(s) of distinct antibody subsets in producing a hypercoagulable state in different patient subsets with antiphospholipid antibody syndromes. ..
  26. ANTIPHOSPHOLIPID SYNDROME AND THE PROTEIN C PATHWAY
    Robert Roubey; Fiscal Year: 2000
    ....
  27. Antiphospholipid Antibody Heterogeneity
    Neal Rote; Fiscal Year: 2007
    The Antiphospholipid Syndrome is characterized by naturally occurring antiphospholipid antibodies and increased risk of pregnancy loss or a variety of obstetric complications...
  28. Isolation of Autoantibodies to Apoptotic Cells
    Marko Radic; Fiscal Year: 2004
    ..The results of these studies will allow a fuller assessment of the role of apoptotic cells in the induction of B cell tolerance or autoimmunity. ..
  29. SIXTH INT CONFERENCE ON SYSTEMIC LUPUS ERYTHEMATOSUS
    Michael Lockshin; Fiscal Year: 2001
    ..to be highlighted in plenary sessions are: pathogenesis, accelerated atheroma, autoimmune response, antiphospholipid syndrome, autoantibodies as cause, prognosis and future research...
  30. TREATMENT STRATEGIES FOR THE ANTI PHOSPHOLIPID SYNDROME
    JOHN DEDMAN; Fiscal Year: 2003
    b>Antiphospholipid Syndrome (APS), also known as Hughes Syndrome, is a multiorgan vascular disease associated with myocardial infarction, stroke thrombosis and recurrent fetal loss...
  31. ANTIPHOSPHOLIPID SYNDROME REGISTRY (APSCORE)
    Robert Roubey; Fiscal Year: 2000
    This contract is for a Registry and Repository for Antiphospholipid Syndrome (APS) that will enable investigators to identify basic immunological and genetic abnormalities, pathophysiological mechanisms contributing to thrombosis, fetal ..
  32. AN ELISA KIT SPECIFIC FOR THE ANTI PHOSPHOLIPID SYNDROME
    EON HARRIS; Fiscal Year: 1993
    The AntiPhospholipid Syndrome (APS) is a disorder of recurrent arterial or venous thromboses and recurrent fetal loss affecting a small population of young people...
  33. Mechanism of aPL antibody-induced Pregnancy loss
    Jane E Salmon; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The antiphospholipid syndrome (APS) is characterized by thrombosis and pregnancy loss that occur in the presence of antiphospholipid (aPL) antibodies...
  34. Reduction of Annexin A5 in Antipholipid Pregnancy Loss
    JACOB RAND; Fiscal Year: 2010
    Recurrent pregnancy losses are a hallmark of the antiphospholipid syndrome (APS), a complicated major hypercoagulable disorder without an established mechanism that is currently diagnosed with phenomenologic surrogate tests...
  35. Complement as a Mediator of Recurrent Miscarriages
    Jane Salmon; Fiscal Year: 2008
    ..In addition, our studies will provide insights into mechanisms by which complement-induces disease and suggest means to prevent, arrest, or modify complement-mediated inflammatory disorders. [unreadable] [unreadable]..
  36. Targets for New Therapeutics for SLE
    Jane Salmon; Fiscal Year: 2002
    ..abstract_text> ..
  37. AUTOIMMUNE MECHANISMS OF THROMBOSIS
    Robert Roubey; Fiscal Year: 2004
    The Antiphospholipid Syndrome (APS) represents an interface between the immune system and blood coagulation...
  38. Cognitive dysfunction in neuropsychiatric-SLE
    Michael Lockshin; Fiscal Year: 2002
    ..Successful completion of this research will redefine the pathogenesis of cognitive dysfunction and suggest therapeutic targets for intervention...
  39. SPORADIC MECHANISM OF THE ANTIPHOSPHOLIPID SYNDROME
    Joan Merrill; Fiscal Year: 2001
    ..Therefore, possible modulation by sex-hormones of interactions between these proteins will be addressed in this application. ..
  40. PREDICTORS OF NEUROPSYCHIATRIC SLE
    ROBIN BREY; Fiscal Year: 2004
    ..The information gained will bridge important gaps in our knowledge about NS involvement in SLE and will lead to new hypothesis-driven studies of etiopathogenesis and treatment. ..
  41. Cognitive Function in SLE (COGNITION)
    Robin L Brey; Fiscal Year: 2010
    ..The information that will be gained from this study is essential for the successful discovery of biological processes that impact on cognitive function in SLE that could be potentially amenable to disease-reversing therapies. ..
  42. MIDCAREER INVESTIGATOR AWARD IN PATIENT-ORIENTED RESEAR
    ROBIN BREY; Fiscal Year: 2006
    ..Much will be learned about the relative importance of genetic factors and autoantibodies on vascular disease risk in SLE that is likely to apply to other populations also at increased risk for cerebral ischemia and vascular dementia. ..
  43. Polymorphisms of Antiphospholipid Protein Antigens
    Joan Merrill; Fiscal Year: 2005
    The antiphospholipid syndrome (APS) is a life-threatening thrombotic disorder characterized by a spectrum of autoantibodies that interfere with blood clotting...
  44. Brain Connections
    Michelle Petri; Fiscal Year: 2006
    ..abstract_text> ..
  45. ANTICARDIOLIPIN ANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME
    Pojen Chen; Fiscal Year: 2007
    ..of this project are to identify and characterize pathogenic anticardiolipin antibodies (aCL) in the antiphospholipid syndrome (APS)...
  46. Revision of ACR Classification Criteria for Systemic Lupus Erythematosus
    Michelle Petri; Fiscal Year: 2007
    ..This project will lead to updated, validated SLE classification criteria that can be immediately used by both industry and academic clinical trials. ..
  47. STRUCTURE/FUNCTION ANALYSIS OF THE UROKINASE RECEPTOR
    Douglas Cines; Fiscal Year: 2002
    ..abstract_text> ..
  48. DEFENSIN AND THE PATHOGENESIS OF ATHEROSCLEROSIS
    Douglas Cines; Fiscal Year: 2002
    ..Finally, the interaction between endogenous defensin and endogenous Lp(a) will be examined in a novel transgenic mouse than overexpresses both human defensin and human Lp(a). ..
  49. Nuclear translocation of urokinase/nucleolin complexes
    Douglas Cines; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  50. Pathophysiology of anti-B2GPI Antibodies in APS
    ALISA WOLBERG; Fiscal Year: 2008
    ..The prevalence of venous thrombosis associated with the primary Antiphospholipid Syndrome (APS) may be as high as 0...
  51. gClqR/p33 in S. Aureus Endovascular Pathogenesis
    Ellinor Peerschke; Fiscal Year: 2005
    ..Results from these studies will define a novel mechanism for S. aureus interactions at sites of endovascular damage, and may identify novel targets for therapeutic intervention. ..
  52. Complement and Ischemic Acute Renal Failure
    JOSHUA THURMAN; Fiscal Year: 2007
    ..The purpose of these studies is to ameliorate ischemic ARF by blocking these pathogenic events, and to develop strategies for decreasing the morbidity and mortality associated with ischemic ARF in humans. ..
  53. Complement Activation and Renal Ischemia/Reperfusion Injury
    JOSHUA THURMAN; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  54. Genetics, Exposures, and RA-Related Autoimmunity
    Kevin Deane; Fiscal Year: 2008
    ....
  55. Inverted Laser-Scanning Confocal Microscope
    Douglas Taatjes; Fiscal Year: 2004
    ..It will also afford the capacity for advanced high-quality imaging capabilities and ensure sustained and efficient use for the UVM biomedical research community for the future. ..
  56. MRFASS--MINORITIES, RISK FACTOR AND STROKE STUDY
    Stanley Tuhrim; Fiscal Year: 2003
    ..Stroke-free survival rates will be estimated for each ethnic group and the independent determinants of recurrence will be identified with multivariate statistical techniques. ..
  57. Individual Propensity to Venous Thrombosis
    John Heit; Fiscal Year: 2009
    ..However, the incidence of VTE has remained relatively constant at about 1 per 1000 since 1980. Clearly, better methods of targeting VTE prophylaxis are needed. ..
  58. MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT
    Emily Von Scheven; Fiscal Year: 2005
    ..Furthermore, development of this well characterized SLE cohort will serve as an important future resource and builds a foundation for studying many lifelong effects of childhood-onset SLE. ..
  59. Studies in Scleroderma and Cystic Fibrosis Osteoporosis
    Peter Merkel; Fiscal Year: 2005
    ..A unique seminar and a series of support services at the host institution will further complement the training program. ..